PYC Therapeutics Advances PKD Trial with Third Cohort Dosing Approval

PYC Therapeutics advances PKD trial with third cohort dosing approval

PYC Therapeutics (ASX: PYC) has received approval from its Safety Review Committee to escalate dosing to the third patient cohort in its Phase 1 Polycystic Kidney Disease trial. The PYC Therapeutics PKD Trial Dosing milestone follows a review of 4-week safety data from the first two cohorts (B1 and B2) treated with PYC-003, the Company’s drug candidate targeting the underlying genetic cause of PKD.

The approval to progress to cohort B3 represents continued forward momentum in Part B of the Single Ascending Dose (SAD) study, which is evaluating PYC-003 in PKD patients. This follows completion of Part A in healthy volunteers, where the drug was assessed across four dose levels ranging from 0.4 mg/kg to 4.0 mg/kg.

For investors, dose escalation approval signals that PYC-003 has demonstrated acceptable safety at lower doses, de-risking the development pathway and maintaining the timeline toward registrational studies.

Understanding Single Ascending Dose trials and why dose escalation matters

A Single Ascending Dose (SAD) study is a type of early-stage clinical trial designed to evaluate how a drug behaves at different dose levels. The primary goal is to identify the maximum tolerated dose while assessing safety and tolerability in humans.

In a SAD study, participants receive a single dose of the drug and are monitored for adverse effects over a defined period (typically 4 weeks in PYC’s trial). An independent Safety Review Committee reviews the safety data from each cohort before approving escalation to the next higher dose level.

Dose escalation approval is a meaningful clinical milestone because it indicates:

1. The drug has demonstrated acceptable safety at the current dose level
2. No dose-limiting toxicities have been observed that would halt the trial
3. The study can progress toward identifying the optimal therapeutic dose
4. The independent safety oversight has validated the risk-benefit profile

For investors unfamiliar with biotech terminology, this represents tangible clinical progress rather than routine process. Each cohort completion brings PYC-003 closer to determining the dose that balances safety with efficacy, a critical step before advancing to later-stage trials.

Clinical development pathway from Phase 1 to registration

PYC’s integrated Phase 1a/1b study is structured across three parts. Part A evaluated PYC-003 in healthy volunteers across four ascending dose cohorts (0.4 mg/kg, 1.2 mg/kg, 2.4 mg/kg, and 4.0 mg/kg) and has been completed. Part B is currently dosing PKD patients, with cohort B3 now approved to commence following the Safety Review Committee’s assessment.

Following completion of Parts A and B, the Company plans to initiate Part C, an Open-Label Multiple Ascending Dose (MAD) study. This study will evaluate repeat dosing and help determine the optimal dosing regimen for PYC-003.

Successful completion of the Phase 1a/1b programme is intended to lead to a registrational combined Phase 2/3 trial, which would support a New Drug Application for PYC-003.

The structured pathway provides investors with clear visibility on upcoming catalysts. Each completed phase de-risks the asset and brings PYC-003 closer to potential commercialisation, with the Phase 2/3 trial representing the pivotal study that could support regulatory approval.

Efficacy endpoints and 24-month data outlook

While the primary objective of the ongoing Phase 1a/1b study is to evaluate the safety and tolerability profile of PYC-003, the trial also includes a secondary objective to assess efficacy in PKD patients. This dual focus allows the Company to gather preliminary efficacy signals while establishing the drug’s safety profile.

The study is measuring two key biomarkers:

• Total Kidney Volume (TKV): A measure of kidney size, which typically increases in PKD patients as cysts grow
• Estimated Glomerular Filtration Rate (eGFR): A measure of kidney function, which typically declines as PKD progresses

PYC has stated it will update shareholders on safety and efficacy data over the coming 24 months as data becomes available from the Phase 1a/1b programme.

The 24-month data outlook provides investors with a tangible timeline for future catalysts. Unlike safety data, which can be assessed relatively quickly after dosing, efficacy endpoints in PKD require longer observation periods to detect meaningful changes in kidney volume and function. The biomarker focus demonstrates a clear path to demonstrating clinical benefit, as both TKV and eGFR are established measures used to assess disease progression in PKD.

For investors, the upcoming data releases represent multiple potential value inflection points, with both safety readouts from higher dose cohorts and preliminary efficacy signals from longitudinal follow-up.

PYC’s broader clinical pipeline and precision medicine platform

PYC-003 is one of three clinical-stage drug development programmes currently being advanced by PYC Therapeutics. The Company positions itself as a precision medicine biotechnology firm creating a new generation of RNA therapies for patients with genetic diseases.

PYC utilises a proprietary drug delivery platform designed to enhance the potency of RNA therapeutics. The platform technology enables more effective delivery of RNA-based drugs to target tissues, potentially improving therapeutic outcomes while reducing required doses.

The Company’s strategic focus on monogenic diseases (conditions caused by mutations in a single gene) reflects a deliberate approach to maximising clinical development success. According to research cited by PYC, monogenic diseases represent the indications with the highest likelihood of success in clinical development.

Strategic Focus on Monogenic Diseases

PYC’s drug development programmes target monogenic diseases, which represent the indications with the highest likelihood of success in clinical development compared to more complex polygenic conditions.

For investors, the three-programme pipeline provides diversification beyond PYC-003, reducing single-asset risk. The proprietary platform technology suggests potential for multiple future candidates beyond the current clinical portfolio, as the delivery system could be applied to other RNA therapeutics targeting different genetic diseases.

The focus on monogenic diseases also aligns with the growing body of evidence supporting precision medicine approaches, where treatments target specific genetic mutations rather than broad disease categories. This approach has demonstrated higher clinical success rates and faster regulatory pathways, potentially accelerating the timeline to commercialisation for PYC’s pipeline assets.

Don’t Miss the Next Biotech Breakthrough

Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving healthcare announcements hit the ASX.